STOCK TITAN

Apyx Medical Corporation - APYX STOCK NEWS

Welcome to our dedicated page for Apyx Medical Corporation news (Ticker: APYX), a resource for investors and traders seeking the latest updates and insights on Apyx Medical Corporation stock.

About Apyx Medical Corporation

Apyx Medical Corporation (NASDAQ: APYX) is an advanced energy technology company specializing in the development, manufacturing, and marketing of innovative medical devices for the cosmetic and surgical markets worldwide. With a strong focus on leveraging proprietary technologies, Apyx delivers cutting-edge solutions that elevate surgical precision and aesthetic outcomes.

The company operates through two primary business segments: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment is centered around its patented Helium Plasma Platform Technology, which is marketed under the Renuvion brand name in the cosmetic surgery market and as J-Plasma in the hospital surgical market. These technologies enable surgeons to achieve unparalleled precision in cutting, coagulation, and ablation of soft tissue while minimizing unintended tissue trauma. The Renuvion system, in particular, empowers plastic surgeons, facial plastic surgeons, and cosmetic physicians to deliver controlled heat to tissue, enhancing patient outcomes in body contouring and other aesthetic procedures.

In addition to its proprietary technologies, Apyx's OEM segment designs, develops, and manufactures electrosurgical generators and related accessories for other medical device manufacturers. This segment leverages the company's decades of expertise in advanced waveforms, allowing it to establish strategic partnerships and diversify its revenue streams.

Industry Position and Market Impact

Apyx Medical Corporation operates at the intersection of the medical device and cosmetic surgery industries, addressing a growing demand for minimally invasive and precise surgical solutions. The company's Renuvion and J-Plasma technologies are supported by extensive clinical validation, with over 90 published clinical documents attesting to their efficacy and safety. This robust evidence base enhances the company's credibility and fosters trust among surgeons and patients alike.

By focusing on innovation and quality, Apyx distinguishes itself in a competitive landscape that includes other advanced energy technology providers. Its ability to address both cosmetic and surgical applications positions it uniquely within its market segments, catering to a diverse customer base that spans hospitals, surgery centers, and private practices.

Commitment to Innovation and Quality

As a company formerly known as Bovie Medical Corporation, Apyx has a legacy of expertise in energy-based medical technologies. Its ongoing commitment to research and development ensures that it remains at the forefront of surgical innovation. By integrating advanced technology with user-centric design, Apyx continues to enhance the capabilities of surgeons and improve patient outcomes.

Conclusion

Apyx Medical Corporation exemplifies the convergence of innovation, precision, and clinical excellence in the medical device industry. Through its proprietary Helium Plasma Platform Technology and strategic OEM partnerships, the company addresses critical needs in both surgical and cosmetic markets. With a focus on delivering transformative solutions and maintaining rigorous quality standards, Apyx is well-positioned to drive meaningful advancements in the field of energy-based medical devices.

Rhea-AI Summary
Apyx Medical Corporation announced the publication of a peer-reviewed article in the Aesthetic Surgery Journal Open Forum, which evaluated the use of Renuvion for contracting subcutaneous soft tissue following liposuction in multiple areas of the body. The analysis of data from 483 patients found no new or increased risks for any area of the body compared to the use of liposuction alone. The study demonstrated Renuvion's impressive safety when used after liposuction, which led to securing FDA 510(k) clearance for the use of Renuvion APR Handpiece. The authors concluded that the use of Renuvion following liposuction for any particular area of the body demonstrated no new or increased risks compared to published data for patients having liposuction performed alone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.03%
Tags
none
-
Rhea-AI Summary
Apyx Medical Corporation (NASDAQ:APYX) reported preliminary revenue results for the fourth quarter and full year ended December 31, 2023. Total revenue for Q4 2023 was approximately $14.2 to $14.6 million, representing 13% to 16% year-over-year growth. Full year 2023 revenue was approximately $51.9 to $52.3 million, showing 17% to 18% year-over-year growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.08%
Tags
none
-
Rhea-AI Summary
Apyx Medical Corporation (APYX) announced a new $45 million credit agreement with Perceptive Credit Holdings IV, LP, providing access to additional capital at more attractive terms. The facility includes senior, secured term loans, with an initial loan of $37.5 million fully drawn at closing. The agreement matures on November 8, 2028, with an initial loan of $37.5 million and a delayed draw loan of $7.5 million. The loans bear interest at a floating rate based on one-month SOFR, subject to a floor of 5.0%, plus 7.0%. The Perceptive Credit Agreement provides for 48 months of interest-only payments, with subsequent monthly payments of 3.0% of the outstanding balance. The obligations under the facility are secured by first priority liens on substantially all of the Company's assets. In connection with the initial loan, the Company issued Perceptive warrants to purchase up to 1,250,000 shares of its common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.29%
Tags
none
Rhea-AI Summary
Apyx Medical Corporation (NASDAQ:APYX) reported a 39% year-over-year increase in Q3 Advanced Energy sales, reaching $9.8 million. The Company also announced a new credit agreement and updated its financial expectations for the full year. The third quarter results showed a 31% year-over-year increase in total revenue to $12.0 million, with a net loss of $4.6 million. The updated guidance for 2023 includes a total revenue range of $53.0 million to $54.0 million, representing a 19% to 21% year-over-year growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.29%
Tags
-
Rhea-AI Summary
Apyx Medical Corporation (NASDAQ:APYX) announced its participation in upcoming investor conferences, including the Stephens Annual Investment Conference, Craig-Hallum 14th Annual Alpha Select Conference, and Piper Sandler 35th Annual Healthcare Conference. Management will engage in fireside chats and 1x1 meetings, with audio webcasts available for replay on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Apyx Medical Corporation will release its financial results for Q3 of fiscal year 2023 on November 9th. A conference call will be held to discuss the results and a webcast will be available. A telephonic replay will also be accessible.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.63%
Tags
Rhea-AI Summary
Apyx Medical Corporation reports Q2 2023 financial results, with total revenue of $13.6 million, up 32% YoY. Advanced Energy revenue increased 40% YoY to $11.7 million. Net loss attributable to stockholders decreased 82% YoY to $1.0 million. Company reaffirms financial guidance for full year 2023, expecting total revenue in the range of $59.0 million to $62.0 million, representing growth of approximately 33% to 39% YoY.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.1%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.93%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.74%
Tags

FAQ

What is the current stock price of Apyx Medical Corporation (APYX)?

The current stock price of Apyx Medical Corporation (APYX) is $1.18 as of March 6, 2025.

What is the market cap of Apyx Medical Corporation (APYX)?

The market cap of Apyx Medical Corporation (APYX) is approximately 45.2M.

What does Apyx Medical Corporation specialize in?

Apyx specializes in advanced energy medical devices, including its proprietary Helium Plasma Platform Technology for cosmetic and surgical applications.

What are Apyx's primary product offerings?

Apyx offers the Renuvion system for cosmetic surgery and the J-Plasma system for hospital surgical use, both leveraging helium plasma technology.

How does Apyx generate revenue?

Apyx generates revenue through its Advanced Energy segment, which includes proprietary technologies, and its OEM segment, which manufactures devices for other companies.

What markets does Apyx serve?

Apyx serves the cosmetic surgery and hospital surgical markets, as well as medical device manufacturers through its OEM partnerships.

What differentiates Apyx from competitors?

Apyx stands out with its patented Helium Plasma Platform Technology, extensive clinical validation, and dual focus on cosmetic and surgical applications.

What is the Renuvion system used for?

The Renuvion system is used by plastic surgeons and cosmetic physicians to deliver controlled heat to tissue for body contouring and other aesthetic procedures.

What is the J-Plasma system designed for?

The J-Plasma system is designed for hospital surgical use, providing surgeons with precise tools for cutting, coagulation, and ablation of soft tissue.

What is Apyx's approach to innovation?

Apyx focuses on leveraging proprietary technologies and extensive R&D to deliver advanced, clinically validated solutions for surgeons and patients.

Does Apyx have strategic partnerships?

Yes, Apyx has OEM partnerships where it designs and manufactures electrosurgical generators and accessories for other medical device manufacturers.

What is Apyx's legacy in the medical device industry?

Formerly known as Bovie Medical Corporation, Apyx has decades of expertise in energy-based medical technologies, emphasizing quality and innovation.
Apyx Medical Corporation

Nasdaq:APYX

APYX Rankings

APYX Stock Data

45.17M
35.04M
16.18%
40.43%
0.68%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
CLEARWATER